Skip to main content
. 2015 Jul 20;10(7):e0132496. doi: 10.1371/journal.pone.0132496

Fig 4. Effects of dehydroxymethylepoxyquinomicin (DHMEQ) on cytokines release by monocytes from cancer patients with and without DVT.

Fig 4

Monocytes were treated or not with 10 μg/mL DHMEQ, after which the amounts of interleukins (IL)-6, tumor necrosis factor alpha (TNF-α), IL-1β and vascular endothelial growth factor (VEGF) secreted were measured by enzyme-linked immunosorbent assay (ELISA). Monocytes were incubated for 24 hr. The treatment with DHMEQ induces the decrease of all molecules in both groups of cancer patients with and without DVT compared to untreated cells (P<0.0001), (t-test). The results are shown as the means ± SD. DVT, Deep Vein thrombosis;